Expansion into new markets
Aerocrine products are widely accepted by international opinion leaders and are now supported by over 1500 published articles.

In Europe, especially Germany, Aerocrine products are used by the vast majority of primary care asthma specialists. In the US, regulatory approval has been gained for NIOX and NIOX MINO. Aerocrine has signed distribution agreements in Japan while regulatory approval has been secured in China for NIOX.

Looking to the future, Aerocrine has developed an effective method for expanding into new markets.

Clinical guidelines
To ensure that the maximum number of patients can benefit, exhaled NO monitoring must be included in national clinical guidelines and local protocols. It is also vital to gain agreement from national healthcare insurance systems to reimburse NO monitoring. This approach has been validated in those markets where Aerocrine has already launched its products such as Germany, Sweden and UK.

The future for Aerocrine
The company is now moving into a more commercial phase with a unique product that meets a need in one of the world’s largest therapy areas. Our overall goal is that people with airways inflammation should feel as well as possible. Our method can make a difference to how people are treated and how they feel. With a more accurate understanding of the underlying disorder, patients can be given the right medication at the right dose, leading to a better quality of life for them and wider economic benefits for society in general.